NanoViricides, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended March 31, 2016. Although the request metadata says “2015 Q3,” the filing itself reports fiscal 2016 third-quarter results. The company is a pre-revenue antiviral drug developer; it reported no product sales or gross margin.
Financial performance and liquidity
| Metric | Three months ended Mar. 31, 2016 | Nine months ended Mar. 31, 2016 | Comparable 2015 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research and development | $1.07 million | $3.43 million | $0.55 million / $2.27 million |
| General and administrative | $0.98 million | $2.94 million | $0.58 million / $2.19 million |
| Net loss | $4.99 million | $9.07 million | $0.25 million / $1.28 million |
| Basic loss per share | $0.09 | $0.16 | $0.00 / $0.02 |
- For the nine months, operating expenses were $6.36 million, up from $4.46 million. The company attributed higher R&D to payroll, lab supplies, and materials; higher G&A reflected staffing and new facilities, partly offset by lower rent.
- Net cash used in operations was $5.45 million for the nine months, versus $4.96 million a year earlier. Investing activities used $0.42 million, primarily for equipment; the prior-year period used $4.56 million for investing. Cash declined $5.87 million to $25.60 million.
- At March 31, 2016, current assets were $25.91 million and current liabilities were $6.62 million; working capital was approximately $19.29 million. Total liabilities were $14.34 million, versus $12.40 million at June 30, 2015. Total assets were $38.32 million and stockholders’ equity was $23.98 million.
- Series B debentures with $6 million principal mature February 1, 2017; their net carrying value was $5.27 million and they were classified as current. Series C debentures have $5 million principal, mature June 30, 2018, and had a $2.96 million net carrying value. Both are convertible and carry interest; Series C and $4 million of Series B debentures are held by entities controlled by a director.
- The company reported $5.20 million in derivative liabilities, measured using Level 3 inputs. Changes in derivative fair value were a $2.32 million expense in the quarter and a $0.92 million expense for the nine months, versus gains in the comparable 2015 periods. These non-cash changes materially affected reported losses.
Changes, outlook, and key risks
- The company said it had sufficient funds to operate through at least March 31, 2018 at its current spending rate, including planned initial clinical-trial spending. It cautioned that higher costs or delays could require reprioritization or additional financing.
- Management prioritized topical HerpeCide programs and injectable FluCide for further preclinical and IND-enabling work. The filing describes animal-study results and ongoing formulation, manufacturing, and safety work; candidates had not entered human trials. Management discussed possible IND submissions and early clinical trials, but timelines and budgets were estimates, not assured guidance.
- The company relocated operations to its Shelton, Connecticut campus and expanded laboratory, virology, scale-up, and cGMP-capable manufacturing capabilities. Equipment validation, process development, and reproducible production batches remained necessary steps before clinical supply.
- Management estimated available cash could support at least one candidate through initial clinical studies, but acknowledged limited clinical-development experience, reliance on outside collaborators and CROs, and uncertainty in cost and timing estimates. The company had no pharmaceutical partner agreement.
- Key risks include continued operating losses, no near-term revenue, clinical and regulatory failure or delay, financing needs beyond the stated runway, dependence on TheraCour Pharma licenses and services, and potentially dilutive debentures, warrants, and stock-based compensation. The filing reported no pending or threatened legal proceedings known to the company.
- Management reported that the material weakness in internal control over financial reporting had not been fully remediated as of March 31, 2016. Disclosure controls and procedures were therefore reported ineffective, despite remediation efforts and added accounting personnel.
- Related-party activity warrants attention: TheraCour charges development fees and other costs, and accounts payable to it was $380,865. The company also issued stock or warrants for compensation and debenture interest, including to director-affiliated holders.
Important facts for investors to verify
- Whether cash burn remains consistent with management’s estimate of funding through March 31, 2018, and how much of that estimate includes clinical-trial costs.
- Progress toward validated manufacturing processes, IND-enabling studies, regulatory submissions, and any human-trial start dates.
- Terms, repayment or conversion outcomes, and dilution implications of the $6 million Series B maturity in February 2017 and the Series C debenture.
- Changes in Level 3 derivative valuations and the assumptions driving reported non-cash gains or losses.
- Whether the disclosed internal-control weakness is remediated and whether controls operate effectively for complex financing and derivative transactions.
- Related-party payments, license dependence on TheraCour, and the availability of alternative funding or commercial partners.